Prime Medicine, Inc.

About Prime Medicine, Inc.

Prime Medicine is dedicated to transforming the lives of patients with debilitating diseases through its innovative Prime Editing platform. The company aims to address the genetic causes of diseases by using a next-generation gene editing approach that searches for and replaces faulty DNA segments with correct copies, potentially offering long-lasting cures and shaping the future of gene editing.

Products & Services

Prime Editing Platform:A next-generation gene editing technology that acts like a DNA word processor to search and replace disease-causing genetic sequences at their precise location in the genome without causing double-strand DNA breakage. It is versatile, precise, and efficient, targeting about 90% of known disease-causing mutations across various organisms, organs, and cell types.

Clinical Programs:Focused therapeutic programs targeting genetic diseases, including large genetic liver diseases and cystic fibrosis, as part of their pipeline.

Specialties

Prime Editing Gene Editing Genetic Disease Treatment DNA Sequence Modification

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 144200000 MR: - FA: $144.2 million FAN: 144200000	D: 2025-08-01 FD: 2025-08-01	3 investors
2	RT: Public Offering T: - FT: Public Offering	A: 125400000 MR: - FA: approximately $125.4 million FAN: 125400000	D: 2025-07-30 FD: 2025-07-30	3 investors
3	RT: Equity and Milestone Funding T: - FT: Equity and Milestone Funding	A: 24000000 MR: - FA: up to $24 million FAN: 24000000	D: 2025-07-16 FD: 2025-07-16	1 investors
4	RT: Grant/Investment T: - FT: Grant/Investment	A: 24000000 MR: - FA: up to $24 million FAN: 24000000	D: 2025-07-16 FD: 2025-07-16	1 investors
5	RT: Public Offering T: - FT: Public Offering	A: 161000000 MR: - FA: approximately $161.0 million FAN: 161000000	D: 2024-02-20 FD: 2024-02-20	5 investors
6	RT: Public Offering T: - FT: Public Offering	A: 140000000 MR: - FA: approximately $140.0 million FAN: 140000000	D: 2024-02-14 FD: 2024-02-14	5 investors
7	RT: Public Offering T: - FT: Public Offering	A: 125000000 MR: - FA: $125.0 million FAN: 125000000	D: 2024-02-14 FD: 2024-02-14	5 investors
8	RT: Grant T: - FT: Grant	A: 15000000 MR: - FA: up to $15 million FAN: 15000000	D: 2024-01-25 FD: 2024-01-25	1 investors
9	RT: Research Funding T: - FT: Research Funding	A: 15000000 MR: - FA: up to $15 million FAN: 15000000	D: 2024-01-25 FD: 2024-01-25	1 investors

Public Offering Latest

2025-08-01

$144.2M

3 investors (Pro only)

Public Offering 2025-07-30

$125.4M

Equity and Milestone Funding 2025-07-16

$24.0M

View 8 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

N

Niamh Alix

Chief Human Resources Officer

R

Ryan Brown

Chief Legal Officer

M

Mohammed Asmal

Chief Medical Officer

A

Ann Lee

CTO

A

Allan Reine

Chief Financial Officer

T

Thomas Cahill

Board Member

View 34 more team members with Pro

Unlock Full Team Directory

Recent News